2g/Day of DHA for 2 Years Has No Impact on Cognition or Hippocampal Volume

Key Takeaways

• 2 g DHA daily for two years showed no cognitive benefit
• Hippocampal volume unchanged in DHA supplementation arm
• EPA‑only formulas may still lower triglycerides and cardiovascular risk
• Omega‑3 Index targets remain <4 % and >8 % for risk stratification
• RCTs increasingly question DHA’s role in brain health

Pulse Analysis

The recent two‑year DHA trial, delivering 2 grams per day, joins a string of high‑quality randomized studies that have failed to confirm the long‑held belief that DHA alone can boost cognition or protect brain structures. While earlier observational work linked higher omega‑3 levels to better memory, those studies could not separate the effects of EPA, DHA, diet, or socioeconomic factors. By measuring both cognitive test scores and hippocampal MRI volumes, the trial provided a rigorous endpoint that showed no statistical advantage over placebo, suggesting that DHA’s neuroprotective promise may have been overstated.

Clinicians and policymakers must now weigh this evidence against the broader omega‑3 literature. The Omega‑3 Index—a combined measure of EPA and DHA in red blood cells—continues to show a U‑shaped relationship with cardiovascular outcomes, with targets below 4 % and above 8 % guiding risk assessment. However, the index does not clarify whether EPA or DHA drives the benefit. EPA‑only products, such as icosapent ethyl, retain proven triglyceride‑lowering and anti‑inflammatory effects, which may explain their continued endorsement for cardiovascular risk reduction, even as DHA’s role in brain health wanes.

For the supplement industry and consumers, the implications are clear: marketing DHA as a cognitive enhancer lacks robust trial support, and future research should prioritize EPA‑rich formulations or whole‑food fish consumption. Investors and health insurers may redirect resources toward interventions with demonstrable outcomes, while researchers are urged to design trials that isolate EPA and DHA effects, adjust for lifestyle confounders, and explore dose‑response curves. In a market saturated with omega‑3 products, evidence‑based guidance will become a key differentiator.